Posted by Cody Wimmer.
Recently AstraZeneca made a statement warning Britain that pharmaceutical companies may be moving out and away from Britain due to their low-funding and exit of the European Union. In Britain, funding for clinical drugs goes through the National Institute for Health and Care Excellence (Nice), “which is based on how cost-effective a drug is.” The issue lies in the fact that many of these drugs are very expensive and serve only to help a few patients with very rare diseases or cases. Nice is not as interested in funding those projects as it is in funding projects that could help more people.
Not only is there a lack of funding from the UK, but since they left the European Union the market in which to sell the products has become much smaller. Before the exit Big Pharma companies could freely trade between the EU with a very little extra cost, but that cost has grown substantially to the point where they might have to look elsewhere. Lisa Anson notes “England spends £6,500 a head on medicines per person. By contrast, in France and Germany it is £12,000 to £13,000.” This shows that not only is the market much smaller in terms of the people that could potentially need the medication, but also that the UK is less willing to spend money on the research and the medication itself.
If the UK does not soon change the way they look at and fund medical treatment they will start to greatly fall behind the rest of Europe, if not the world. They no longer can rely on their European Union trading nor their outdated government health care spending to keep them afloat and keep them ahead in terms of research. If they want to have a chance to keep the pharmaceutical companies in the UK they are going to have to make some major changes in their health care system.
Cody is an information technology management major at the Stillman School of Business, Seton Hall University, Class of 2018.